Prognostic relevance of post-cycle 1 pembrolizumab levels in real-world NSCLC patients receiving first line IO or ChIO
Por:
Martinez C, Alejandre M, de Juan V, Lorduy A, Estevez S, Nunez N, Tain P, Onecha M, Banaclocha N, Peña E, Jiménez-Meseguer M, Martin A, Cabia S, Lopez S, Rogado J, Hernandez A, Sarto J, Gonzalez M, Cruz-Bermudez A, Pulla M
Publicada:
1 mar 2025
Resumen:
|